首页 > 最新文献

European Cardiology Review最新文献

英文 中文
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation 冷冻消融或药物治疗心房颤动的初始治疗
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2021.38
J. Andrade, R. Turgeon, L. Macle, M. Deyell
AF is a common chronic and progressive disorder. Without treatment, AF will recur in up to 75% of patients within a year of their index diagnosis. Antiarrhythmic drugs (AADs) have been proven to be more effective than placebo at maintaining sinus rhythm and remain the recommended initial therapeutic option for AF. However, the emergence of ‘single-shot’ AF ablation toolsets, which have enabled enhanced procedural standardisation and consistent outcomes with low rates of complications, has led to renewed interest in determining whether first-line catheter ablation may improve outcomes. The recently published EARLY-AF trial evaluated the role of initial cryoballoon ablation versus guideline-directed AAD therapy. Compared to AADs, an initial treatment cryoballoon ablation strategy resulted in greater freedom from atrial tachyarrhythmia, superior reduction in AF burden, greater improvement in quality of life and lower healthcare resource utilisation. These findings are relevant to patients, providers and healthcare systems when considering the initial treatment choice for rhythm-control therapy.
房颤是一种常见的慢性进行性疾病。如果不进行治疗,多达75%的AF患者会在其指数诊断后的一年内复发。抗心律失常药物(AADs)已被证明在维持窦性心律方面比安慰剂更有效,并且仍然是房颤推荐的初始治疗选择。然而,“单针”房颤消融工具集的出现,增强了程序标准化和低并发症发生率的一致结果,重新引起了人们对确定一线导管消融是否可以改善结果的兴趣。最近发表的早期房颤试验评估了初始低温球囊消融与指南指导的AAD治疗的作用。与AADs相比,低温球囊消融的初始治疗策略使患者更免于房性心动过速,更好地减轻房颤负担,更大程度地改善生活质量,降低医疗资源利用率。这些发现与患者、提供者和医疗保健系统在考虑心律控制治疗的初始治疗选择时相关。
{"title":"Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation","authors":"J. Andrade, R. Turgeon, L. Macle, M. Deyell","doi":"10.15420/ecr.2021.38","DOIUrl":"https://doi.org/10.15420/ecr.2021.38","url":null,"abstract":"AF is a common chronic and progressive disorder. Without treatment, AF will recur in up to 75% of patients within a year of their index diagnosis. Antiarrhythmic drugs (AADs) have been proven to be more effective than placebo at maintaining sinus rhythm and remain the recommended initial therapeutic option for AF. However, the emergence of ‘single-shot’ AF ablation toolsets, which have enabled enhanced procedural standardisation and consistent outcomes with low rates of complications, has led to renewed interest in determining whether first-line catheter ablation may improve outcomes. The recently published EARLY-AF trial evaluated the role of initial cryoballoon ablation versus guideline-directed AAD therapy. Compared to AADs, an initial treatment cryoballoon ablation strategy resulted in greater freedom from atrial tachyarrhythmia, superior reduction in AF burden, greater improvement in quality of life and lower healthcare resource utilisation. These findings are relevant to patients, providers and healthcare systems when considering the initial treatment choice for rhythm-control therapy.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84460596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Chest Pain in the Cancer Patient 癌症患者的胸痛
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2021.45
S. Tyebally, Aruni Ghose, Daniel H. Chen, A. Abiodun, Arjun K. Ghosh
Chest pain is one of the most common presenting symptoms in patients seeking care from a physician. Risk assessment tools and scores have facilitated prompt diagnosis and optimal management in these patients; however, it is unclear as to whether a standardised approach can adequately triage chest pain in cancer patients and survivors. This is of concern because cancer patients are often at an increased risk of cardiovascular mortality and morbidity given the shared risk factors between cancer and cardiovascular disease, compounded by the fact that certain anti-cancer therapies are associated with an increased risk of cardiovascular events that can persist for weeks and even years after treatment. This article describes the underlying mechanisms of the most common causes of chest pain in cancer patients with an emphasis on how their management may differ to that of non-cancer patients with chest pain. It will also highlight the role of the cardio-oncology team, who can aid in identifying cancer therapy-related cardiovascular side-effects and provide optimal multidisciplinary care for these patients.
胸痛是寻求医生护理的患者最常见的症状之一。风险评估工具和评分促进了这些患者的及时诊断和最佳管理;然而,目前尚不清楚是否有一种标准化的方法可以对癌症患者和幸存者的胸痛进行适当的分类。由于癌症和心血管疾病之间存在共同的风险因素,加之某些抗癌疗法与心血管事件的风险增加有关,这种风险可能在治疗后持续数周甚至数年,因此癌症患者心血管死亡和发病率的风险往往会增加,这一点令人担忧。这篇文章描述了癌症患者胸痛最常见原因的潜在机制,并强调了他们的治疗与非癌症患者胸痛的不同之处。它还将强调心脏肿瘤学团队的作用,他们可以帮助识别癌症治疗相关的心血管副作用,并为这些患者提供最佳的多学科护理。
{"title":"Chest Pain in the Cancer Patient","authors":"S. Tyebally, Aruni Ghose, Daniel H. Chen, A. Abiodun, Arjun K. Ghosh","doi":"10.15420/ecr.2021.45","DOIUrl":"https://doi.org/10.15420/ecr.2021.45","url":null,"abstract":"Chest pain is one of the most common presenting symptoms in patients seeking care from a physician. Risk assessment tools and scores have facilitated prompt diagnosis and optimal management in these patients; however, it is unclear as to whether a standardised approach can adequately triage chest pain in cancer patients and survivors. This is of concern because cancer patients are often at an increased risk of cardiovascular mortality and morbidity given the shared risk factors between cancer and cardiovascular disease, compounded by the fact that certain anti-cancer therapies are associated with an increased risk of cardiovascular events that can persist for weeks and even years after treatment. This article describes the underlying mechanisms of the most common causes of chest pain in cancer patients with an emphasis on how their management may differ to that of non-cancer patients with chest pain. It will also highlight the role of the cardio-oncology team, who can aid in identifying cancer therapy-related cardiovascular side-effects and provide optimal multidisciplinary care for these patients.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85359042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multimodality Imaging to Explore Sex Differences in Aortic Stenosis. 多模态成像探讨主动脉瓣狭窄的性别差异。
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2022.26
Gurpreet K Singh, Victoria Delgado

The aim of this article is to review sex differences in aortic stenosis (AS) assessed with multimodality imaging. Echocardiography remains the mainstay imaging technique to diagnose AS and provides important insights into the differences between men and women in relation to valve haemodynamic and left-ventricular response. However, echocardiography does not have adequate resolution to provide important insights into sex differences in the degenerative, calcific pathophysiological process of the aortic valve. CT shows that women with AS have more fibrotic changes of the aortic valve whereas men show more calcific deposits. Cardiac magnetic resonance shows that women have left ventricles that are less hypertrophic and smaller compared with those of men, while men have more replacement myocardial fibrosis. These differences may lead to different responses to aortic valve replacement because myocardial diffuse fibrosis but not replacement myocardial fibrosis may regress after the procedure. Sex differences in the pathophysiological process of AS can be assessed using multimodality imaging, assisting in decisionmaking in these patients.

本文的目的是回顾多模态成像评估主动脉瓣狭窄(AS)的性别差异。超声心动图仍然是诊断AS的主要成像技术,并为男性和女性在瓣膜血流动力学和左心室反应方面的差异提供了重要见解。然而,超声心动图没有足够的分辨率来提供主动脉瓣退行性钙化病理生理过程中的性别差异的重要见解。CT显示女性AS患者主动脉瓣有更多的纤维化改变,而男性则有更多的钙化沉积。心脏磁共振显示,与男性相比,女性的左心室肥厚较小,而男性则有更多的替代心肌纤维化。这些差异可能导致对主动脉瓣置换术的不同反应,因为心肌弥漫性纤维化而非置换性心肌纤维化可能在手术后消退。AS病理生理过程中的性别差异可以通过多模态成像来评估,有助于这些患者的决策。
{"title":"Multimodality Imaging to Explore Sex Differences in Aortic Stenosis.","authors":"Gurpreet K Singh,&nbsp;Victoria Delgado","doi":"10.15420/ecr.2022.26","DOIUrl":"https://doi.org/10.15420/ecr.2022.26","url":null,"abstract":"<p><p>The aim of this article is to review sex differences in aortic stenosis (AS) assessed with multimodality imaging. Echocardiography remains the mainstay imaging technique to diagnose AS and provides important insights into the differences between men and women in relation to valve haemodynamic and left-ventricular response. However, echocardiography does not have adequate resolution to provide important insights into sex differences in the degenerative, calcific pathophysiological process of the aortic valve. CT shows that women with AS have more fibrotic changes of the aortic valve whereas men show more calcific deposits. Cardiac magnetic resonance shows that women have left ventricles that are less hypertrophic and smaller compared with those of men, while men have more replacement myocardial fibrosis. These differences may lead to different responses to aortic valve replacement because myocardial diffuse fibrosis but not replacement myocardial fibrosis may regress after the procedure. Sex differences in the pathophysiological process of AS can be assessed using multimodality imaging, assisting in decisionmaking in these patients.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/44/7b/ecr-17-e26.PMC9947932.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10792895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Obituary: C Richard Conti, MD 讣告:理查德·孔蒂,医学博士
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2022.21
C. Pepine
{"title":"Obituary: C Richard Conti, MD","authors":"C. Pepine","doi":"10.15420/ecr.2022.21","DOIUrl":"https://doi.org/10.15420/ecr.2022.21","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73716359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular Complications of Chronic Kidney Disease: An Introduction 慢性肾脏疾病的心血管并发症:介绍
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2021.54
H. Warrens, D. Banerjee, C. Herzog
{"title":"Cardiovascular Complications of Chronic Kidney Disease: An Introduction","authors":"H. Warrens, D. Banerjee, C. Herzog","doi":"10.15420/ecr.2021.54","DOIUrl":"https://doi.org/10.15420/ecr.2021.54","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86308283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Socioeconomic Factors and their Impact on Access and Use of Coronary and Structural Interventions. 社会经济因素及其对冠状动脉和结构干预的获取和使用的影响。
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2022.23
Renee P Bullock-Palmer, Katia Bravo-Jaimes, Mamas A Mamas, Cindy L Grines

In the past few decades, the accelerated improvement in technology has allowed the development of new and effective coronary and structural heart disease interventions. There has been inequitable patient access to these advanced therapies and significant disparities have affected patients from low socioeconomic positions. In the US, these disparities mostly affect women, black and hispanic communities who are overrepresented in low socioeconomic. Other adverse social determinants of health influenced by structural racism have also contributed to these disparities. In this article, we review the literature on disparities in access and use of coronary and structural interventions; delineate the possible reasons underlying these disparities; and highlight potential solutions at the government, healthcare system, community and individual levels.

在过去的几十年里,技术的加速进步使得新的有效的冠状动脉和结构性心脏病干预措施得以发展。患者获得这些先进疗法的机会不公平,社会经济地位较低的患者受到显著差异的影响。在美国,这些差异主要影响女性、黑人和西班牙裔社区,这些群体在社会经济地位较低的群体中所占比例过高。受结构性种族主义影响的其他不利的健康社会决定因素也助长了这些差异。在这篇文章中,我们回顾了在获取和使用冠状动脉和结构干预方面的差异的文献;描述造成这些差异的可能原因;并强调在政府、医疗系统、社区和个人层面的潜在解决方案。
{"title":"Socioeconomic Factors and their Impact on Access and Use of Coronary and Structural Interventions.","authors":"Renee P Bullock-Palmer,&nbsp;Katia Bravo-Jaimes,&nbsp;Mamas A Mamas,&nbsp;Cindy L Grines","doi":"10.15420/ecr.2022.23","DOIUrl":"https://doi.org/10.15420/ecr.2022.23","url":null,"abstract":"<p><p>In the past few decades, the accelerated improvement in technology has allowed the development of new and effective coronary and structural heart disease interventions. There has been inequitable patient access to these advanced therapies and significant disparities have affected patients from low socioeconomic positions. In the US, these disparities mostly affect women, black and hispanic communities who are overrepresented in low socioeconomic. Other adverse social determinants of health influenced by structural racism have also contributed to these disparities. In this article, we review the literature on disparities in access and use of coronary and structural interventions; delineate the possible reasons underlying these disparities; and highlight potential solutions at the government, healthcare system, community and individual levels.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/d7/ecr-17-e19.PMC9820075.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10533510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The DELIVER Trial: the Beginning of the End of Ejection Fraction Tyranny. 交付审判:结束射血分数暴政的开始。
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2022.44
Antoni Bayes-Genis

It has been reported at the 2022 European Society of Cardiology Congress that the DELIVER trial has met its primary outcome - a relative reduction of 18% in a composite of worsening heart failure (HF) or cardiovascular death. These results, added to evidence from previously reported pivotal trials with sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with reduced and preserved heart failure (HF), provide compelling evidence of the benefit of SGLT2is across the HF spectrum, irrespective of ejection fraction. New diagnostic algorithms that are quick and easy to implement at the point of care are needed for quick diagnosis and implementation of these drugs. Ejection fraction may come later for proper phenotyping.

据2022年欧洲心脏病学会大会报道,DELIVER试验达到了其主要终点——心衰(HF)恶化或心血管死亡的复合发生率相对降低18%。这些结果,加上先前报道的钠-葡萄糖共转运蛋白-2抑制剂(SGLT2is)在减少性和保存性心力衰竭(HF)患者中的关键试验的证据,提供了令人信服的证据,证明SGLT2is在HF频谱上的益处,无论射血分数如何。为了快速诊断和实施这些药物,需要在护理点快速简便地实施新的诊断算法。射血分数可能晚于正确的表型。
{"title":"The DELIVER Trial: the Beginning of the End of Ejection Fraction Tyranny.","authors":"Antoni Bayes-Genis","doi":"10.15420/ecr.2022.44","DOIUrl":"https://doi.org/10.15420/ecr.2022.44","url":null,"abstract":"<p><p>It has been reported at the 2022 European Society of Cardiology Congress that the DELIVER trial has met its primary outcome - a relative reduction of 18% in a composite of worsening heart failure (HF) or cardiovascular death. These results, added to evidence from previously reported pivotal trials with sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with reduced and preserved heart failure (HF), provide compelling evidence of the benefit of SGLT2is across the HF spectrum, irrespective of ejection fraction. New diagnostic algorithms that are quick and easy to implement at the point of care are needed for quick diagnosis and implementation of these drugs. Ejection fraction may come later for proper phenotyping.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c7/6d/ecr-17-e30.PMC9947924.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10850768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis 直接口服抗凝剂在术后静脉血栓栓塞预防中的作用
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2021.55
Han Naung Tun, M. T. Kyaw, E. Rafflenbeul, Xiuhtlaulli López Suástegui
Venous thromboembolism (VTE) is one of the leading causes of post-operative morbidity and mortality. Over previous decades, heparin and warfarin were the predominant therapeutic options for post-operative thromboprophylaxis. However, their use is limited by drawbacks including a narrow therapeutic range, numerous food and drug interactions, and the need for regular monitoring for dose adjustments. Recently, direct oral anticoagulants (DOACs), such as dabigatran etexilate (a direct thrombin inhibitor) and apixaban, rivaroxaban and edoxaban (direct factor Xa inhibitors), have been developed to overcome these issues. DOACs have shown promising results in Phase III clinical trials for post-operative VTE prophylaxis. This review summarises the pharmacological profile of DOACs and highlights the use of DOACs in post-operative VTE prophylaxis based on the available clinical trial data.
静脉血栓栓塞(VTE)是术后发病率和死亡率的主要原因之一。在过去的几十年里,肝素和华法林是术后血栓预防的主要治疗选择。然而,它们的使用受到一些缺点的限制,包括狭窄的治疗范围,大量的食物和药物相互作用,以及需要定期监测剂量调整。最近,直接口服抗凝剂(DOACs),如达比加群酯(一种直接凝血酶抑制剂)和阿哌沙班、利伐沙班和依多沙班(直接Xa因子抑制剂),已经被开发出来以克服这些问题。DOACs在预防术后静脉血栓栓塞的III期临床试验中显示出令人鼓舞的结果。本文综述了DOACs的药理学概况,并根据现有的临床试验数据强调了DOACs在术后静脉血栓栓塞预防中的应用。
{"title":"Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis","authors":"Han Naung Tun, M. T. Kyaw, E. Rafflenbeul, Xiuhtlaulli López Suástegui","doi":"10.15420/ecr.2021.55","DOIUrl":"https://doi.org/10.15420/ecr.2021.55","url":null,"abstract":"Venous thromboembolism (VTE) is one of the leading causes of post-operative morbidity and mortality. Over previous decades, heparin and warfarin were the predominant therapeutic options for post-operative thromboprophylaxis. However, their use is limited by drawbacks including a narrow therapeutic range, numerous food and drug interactions, and the need for regular monitoring for dose adjustments. Recently, direct oral anticoagulants (DOACs), such as dabigatran etexilate (a direct thrombin inhibitor) and apixaban, rivaroxaban and edoxaban (direct factor Xa inhibitors), have been developed to overcome these issues. DOACs have shown promising results in Phase III clinical trials for post-operative VTE prophylaxis. This review summarises the pharmacological profile of DOACs and highlights the use of DOACs in post-operative VTE prophylaxis based on the available clinical trial data.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81896935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Artificial Intelligence and Cardiovascular Risk Prediction: All That Glitters is not Gold. 人工智能和心血管风险预测:闪光的不一定都是金子。
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2022.11
Mauro Chiarito, Luca Luceri, Angelo Oliva, Giulio Stefanini, Gianluigi Condorelli

Artificial intelligence (AI) is a broad term referring to any automated systems that need 'intelligence' to carry out specific tasks. During the last decade, AI-based techniques have been gaining popularity in a vast range of biomedical fields, including the cardiovascular setting. Indeed, the dissemination of cardiovascular risk factors and the better prognosis of patients experiencing cardiovascular events resulted in an increase in the prevalence of cardiovascular disease (CVD), eliciting the need for precise identification of patients at increased risk for development and progression of CVD. AI-based predictive models may overcome some of the limitations that hinder the performance of classic regression models. Nonetheless, the successful application of AI in this field requires knowledge of the potential pitfalls of the AI techniques, to guarantee their safe and effective use in daily clinical practice. The aim of the present review is to summarise the pros and cons of different AI methods and their potential application in the cardiovascular field, with a focus on the development of predictive models and risk assessment tools.

人工智能(AI)是一个广义的术语,指的是任何需要“智能”来执行特定任务的自动化系统。在过去十年中,基于人工智能的技术在包括心血管疾病在内的广泛生物医学领域越来越受欢迎。事实上,心血管危险因素的传播和经历心血管事件的患者预后的改善导致心血管疾病(CVD)患病率的增加,因此需要精确识别CVD发展和进展风险增加的患者。基于人工智能的预测模型可以克服一些阻碍经典回归模型性能的局限性。然而,人工智能在这一领域的成功应用需要了解人工智能技术的潜在缺陷,以保证其在日常临床实践中的安全有效使用。本综述的目的是总结不同人工智能方法的优缺点及其在心血管领域的潜在应用,重点是预测模型和风险评估工具的发展。
{"title":"Artificial Intelligence and Cardiovascular Risk Prediction: All That Glitters is not Gold.","authors":"Mauro Chiarito,&nbsp;Luca Luceri,&nbsp;Angelo Oliva,&nbsp;Giulio Stefanini,&nbsp;Gianluigi Condorelli","doi":"10.15420/ecr.2022.11","DOIUrl":"https://doi.org/10.15420/ecr.2022.11","url":null,"abstract":"<p><p>Artificial intelligence (AI) is a broad term referring to any automated systems that need 'intelligence' to carry out specific tasks. During the last decade, AI-based techniques have been gaining popularity in a vast range of biomedical fields, including the cardiovascular setting. Indeed, the dissemination of cardiovascular risk factors and the better prognosis of patients experiencing cardiovascular events resulted in an increase in the prevalence of cardiovascular disease (CVD), eliciting the need for precise identification of patients at increased risk for development and progression of CVD. AI-based predictive models may overcome some of the limitations that hinder the performance of classic regression models. Nonetheless, the successful application of AI in this field requires knowledge of the potential pitfalls of the AI techniques, to guarantee their safe and effective use in daily clinical practice. The aim of the present review is to summarise the pros and cons of different AI methods and their potential application in the cardiovascular field, with a focus on the development of predictive models and risk assessment tools.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d5/ae/ecr-17-e29.PMC9947926.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10799438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Highlights of Acute Coronary Syndromes. 急性冠脉综合征的要点。
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2022.49
Alejandro Recio-Mayoral

New evidence for acute coronary syndrome has been presented in Hot Line sessions at the 2022 European Society of Cardiology Congress in Barcelona. This editorial describes some of the highlights.

在巴塞罗那举行的2022年欧洲心脏病学会大会的热线会议上,提出了急性冠状动脉综合征的新证据。这篇社论描述了其中的一些亮点。
{"title":"Highlights of Acute Coronary Syndromes.","authors":"Alejandro Recio-Mayoral","doi":"10.15420/ecr.2022.49","DOIUrl":"https://doi.org/10.15420/ecr.2022.49","url":null,"abstract":"<p><p>New evidence for acute coronary syndrome has been presented in Hot Line sessions at the 2022 European Society of Cardiology Congress in Barcelona. This editorial describes some of the highlights.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a9/7e/ecr-17-e23.PMC9820060.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10533508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Cardiology Review
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1